A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy

Canadian Journal of Psychiatry

Volumn 48, Issue 2, 2003, Pages 106-110

  Einarson, Adrienne ^a,f   Bonari, Lori ^a   Voyer Lavigne, Sharon ^b   Addis, Antonio ^c   Matsui, Doreen ^d   Johnson, Yvette ^e   Koren, Gideon ^a  

^a Motherisk Program   (Canada)

^b Pregnancy Riskline   (United States)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d FRAME Program   (Canada)

^e Michigan Teratogen Info Service   (United States)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Antidepressant; Comparative study; Pregnancy outcome; Teratology

Indexed keywords

NEFAZODONE; TRAZODONE;

ABORTION; ADULT; ARTICLE; CLINICAL TRIAL; CONGENITAL MALFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EXPOSURE; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEMALE; FETOTOXICITY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREGNANCY; PREGNANCY COMPLICATION; PREMATURE LABOR; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; STILLBIRTH; TERATOGENESIS;

EID: 0037356344     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370304800207     Document Type: Article

References (24)

1. Desyrel product monograph. Montreal: Bristol-Myers Squibb; 1970.
2. Serzone product monograph. Montreal: Bristol-Myers Squibb; 1996.
3. Better news on population (notice board). Lancet 1992;339:16.
4. Einarson A, Bailey B, Jung C, Spizziri D, Bailley M, Koren G. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Asthma Immunol 1997;78:183-6.
5. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs due to fears of teratogenic risk and the impact of counseling. J Psychiatry Neurosci 2001;26(1):44-8.
6. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Donnenfeld A, and others. Pregnancy outcome following first trimester exposure to fluoxetine. JAMA 1993;269:2246-8.
7. Kulin N, Pastuszak A, Sage S, Schick-Boschetto B, Spivey G, Feldkamp M, and others. Pregnancy outcome following maternal use of the new serotonin reuptake inhibitors: a prospective multicentre study. JAMA 1998;279:609-10.
8. Chambers CD, Johnson KA, Dick LM, Felix R J, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-5.
9. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardener HA, Theis J, and others. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258-62.
10. Einarson A, Fatoye B, Sarkar M, Lavigne L, Brochu J, Chambers C, and others. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001;158:1728-30.
11. Evans J, Heron J, Francomb H, Oke S, Golding J. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001;323:257-60.
12. Wisner K, Zarin D, Appelbaum P, Gelenberg A, Leonard H, Frank E. Riskbenefit decision making for treatment of depression during pregnancy. Am J Psychiatry 2000;157:1933-40.
13. Chung T, Lau TK, Yip A, Chiu H, Lee D. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med 2001;63:830-4.
14. Marden PM, Smith DW, McDonald MJ. Congenital anomalies in the newborn, including variations. J Pediatr 1964;64:357-71.
15. Shuhaiber S, Pastuszak A, Schick B, Matsui D, Spivey G, Brochu J, and others. Pregnancy outcome following first trimester to sumatriptin. Neurology 1998;51:581-3.
16. Einarson A, Lyszkiewicz DA, Koren G. The safety of dextromethorphan in pregnancy: results of a controlled study. Chest 2001;119:466-9.
17. Atanackovic G, Navioz Y, Moretti ME, Koren G. The safety of higher than standard doses of Diclectin for nausea and vomiting of pregnancy. J Clin Pharmacol 2001;41:842-5.
18. Einarson A, Phillips E, Mawji F, D'Alimonte D, Schick B, Addis A, and others. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol 1998;15:523-5.
19. McElhatton PR, Garbis H, Elefant E, Vial T, Bellemin B, Mastroicova P, and others. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants: a collaborative study of the European Network of Teratology Information Services (ENTIS) Reproductive Toxicology 1996;10:285-94.
20. Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997;89:713-8.
21. Bosquet M, Egeland B. Associations among maternal depressive symptomatology, a state of mind and parent and child behaviours: implications for attachment based intervention. Attachment and Human Development 2001;3:173-99.
22. Lundgren K. Relationship among maternal-fetal attachment prenatal depression and health practices in pregnancy. Res Nurs Health 2001;24:203-17.
23. Kurki T, Hiilesmaa V, Raitasalo R, Mattila H, Ylikorkala O. Depression and anxiety in early pregnancy and risk of preeclampsia. Obstet Gynecol 2000;95:487-90.
24. Stewart DE. Hepatic adverse reactions associated with nefazodone. Can J Psychiatry 2002;47:375-7.